Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 823 results for "gilead sciences"

RBC Capital Increases Gilead Sciences Price Target to $115.00 (GILD)
American Banking News

Zacks Earnings Trends Highlights: Wal-Mart, Target, Macy's, Gi...

CHICAGO, Aug. 29, 2014 /PRNewswire/ -- Zacks Director of Research Sheraz Mian says, "Total earnings for the S&P 500 reached a new all-time quarterly record, and increasing by +8.1% from the same period last year on +4.4% higher revenues" Q2 ... Financial Content, 21 hours ago

102 images for gilead sciences

American Banking News, 1 day ago
Value Walk, 1 week ago
Value Walk, 1 week ago
Value Walk, 1 week ago
Value Walk, 1 week ago
Value Walk, 1 week ago
Value Walk, 1 week ago
Value Walk, 1 week ago
Value Walk, 1 week ago
Value Walk, 1 week ago

Gilead Sciences (GILD) Showing Resistance Near $108.82

Gilead Sciences Inc ("GILD) presents a trading opportunity that offers a 6.06% return in just 50 days. A covered call on Gilead Sciences at the $110.00 level expiring on Oct. '14 offers an ...
 Individual.com15 hours ago Gilead Sciences (GILD) Showing Support Near $101.36  TradingCharts.com4 days ago

Why Gilead Sciences (GILD) Could Be Positioned for a Surge?

Gilead Sciences Inc. ( GILD ) is a healthcare company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front ...
 Yahoo! Finance22 hours ago
Motley Fool

Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than Gilead Sciences

It isn't surprising to see that the European Commission has given Bristol-Myers Squibb (NYSE: BMY Now that Daklinza has the official go-ahead, sales should head markedly higher. If so, Daklinza poses a threat to Johnson & Johnson's (NYSE: JNJ ...
 Motley Fool1 day ago Bristol-Myers's Breakthrough Drug For HCV Gets Approved  Bidness Etc1 day ago Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C  Fierce Biotech IT2 days ago U.S. FDA approves Gilead blood cancer drug Zydelig  Reuters1 month ago
Motley Fool

Has Gilead Sciences, Inc.'s Star Drug Already Peaked?

Gilead Sciences ' ( NASDAQ: GILD ) hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed. First, new prescriptions started to fall in March. And then, as ...
 Motley Fool1 day ago

3 Reasons Sanofi's Stock Could Rise

After a rocky second quarter, biopharma stocks have rallied in a big way heading toward the end of the year. Gilead Sciences , for example, has shot up 41.5% year to date, with most of this upward movement coming in recent weeks. Even so, Sanofi ...
 Motley Fool1 day ago
American Banking News

Achillion Pharmaceuticals, Inc. Hits One Year High After Rumors Gilead Sciences, Inc. Might Buy It Out

Achillion Pharmaceuticals (NASDAQ: ACHN) and Arrowhead Research (NASDAQ: ARWR) were up sharply Tuesday after an analyst said the pair of drug development companies could become takeover targets. "If you want to compete with Gilead, you have to ...
 BioSpace2 days ago Gilead Sciences Sets New 52-Week High at $108.72 (GILD)  American Banking News3 days ago One Factor Driving Gilead Sciences (GILD) Stock Up to a One-Year High Today  TheStreet.com4 days ago Achillion Hits 52-Week High After Rumors Gilead Might Buy It Out  Bidness Etc3 days ago

Highest EPS Growth in the Biotechnology Industry Detected for Gilead Sciences (GILD, VNDA, OPK)

(Financial News Network On) Below are the three companies in the Biotechnology industry with the highest year-over-year expected earnings per share (EPS) growth rates. Gilead Sciences (NASDAQ:GILD) is highest with EPS growth of 274.8%. Gilead ...
 Individual.com2 days ago Gilead Sciences is Among the Companies in the Biotechnology Industry With the Lowest PEG Ratio (GILD, ANIK, ACOR, CELG, ALXN)  Individual.com1 week ago Biosante Pharmaceuticals is Among the Companies in the Biotechnology Industry With the Lowest Forward P/E Ratio (BPAX, PDLI, UTHR, MNTA, GILD)  Comtex SmarTrend3 days ago

Gilead Sciences (GILD) Approaches New Upside Target of $110.54

Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $106.59 and have already reached the first level of resistance at $108.40. Investors may be interested in a cross of the next upside pivot targets of $110.54
 Individual.com2 days ago Next Resistance Level for Gilead Sciences (GILD) is $103.26  Comtex SmarTrend1 week ago Gilead Sciences (GILD) Crosses Pivot Point Resistance at $100.31  Individual.com1 week ago

Gilead Sciences Shares Up 47.7% Since SmarTrend's Buy Recommendation (GILD)

SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 4 months, Gilead Sciences has returned 47.70% as of today's recent price
 Individual.com4 days ago Gilead Sciences Up 37.1% Since SmarTrend Uptrend Call (GILD)  Individual.com2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less